Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONCOS-102 and Pembrolizumab in Advanced Melanoma
NCT03003676Phase 1Completed
- Sponsor
- Targovax
- Start
- Dec 2016
- Primary completion
- Jul 2020
- Modality
- Oncolytic Viruses, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 1, open-label trial of ONCOS-102 in melanoma (2 arms), sponsored by Targovax. Primary endpoint: Incidence of Treatment-emergent Adverse Events at 6 months. Started Dec 2016; status: completed.
02
Drugs
ONCOS-102
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03003676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03003676.